Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001036304 | SCV001199659 | likely benign | Ullrich congenital muscular dystrophy 2; Bethlem myopathy 2 | 2023-12-21 | criteria provided, single submitter | clinical testing | |
Gene |
RCV003148915 | SCV003837160 | uncertain significance | not provided | 2024-03-08 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis supports that this missense variant has a deleterious effect on protein structure/function |
Ce |
RCV003148915 | SCV004185369 | uncertain significance | not provided | 2023-11-01 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV003148915 | SCV005407895 | uncertain significance | not provided | 2024-05-20 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004746203 | SCV005348844 | uncertain significance | COL12A1-related disorder | 2024-09-17 | no assertion criteria provided | clinical testing | The COL12A1 c.8554C>T variant is predicted to result in the amino acid substitution p.Pro2852Ser. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.019% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |